Table 1.

Baseline characteristics of Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial participants with and without eGFR decline

Characteristic, n (%)Subjects with Decline in eGFR (n=98)aSubjects without Decline in eGFR (n=5269)
Age, yr63 (10)61 (10)
Men55 (56)3588 (68)
Race
 White66 (67)3832 (73)
 Asian19 (19)1069 (20)
 Black8 (8)207 (4)
Body mass index (kg/m2), mean±SD31±6.630±5.6
Current smoker6 (6)723 (14)
Years of type 2 diabetes, mean±SD15±9.99±8.1
HbA1c (%), mean±SD8±1.08±1.1
Hypertension90 (92)4369 (83)
Congestive heart failure50 (51)1446 (27)
Percutaneous coronary intervention51 (52)3315 (63)
Coronary artery bypass grafting27 (28)660 (13)
Peripheral arterial disease19 (19)493 (9)
Cerebrovascular diseases13 (13)374 (7)
eGFR (ml/min per 1.73 m2), mean±SD40 (24)75 (21)
Protein-to-creatinine ratio (mg/mg), mean±SDb4.1±4.80.4±1.0
Microalbuminuriac72 (90)1707(56)
Macroalbuminuriad57 (71)444 (15)
Medications
 Antiplatelet agents93 (95)5122 (97)
β blockers79 (81)4325 (82)
 Statins81 (83)4778 (91)
 Calcium-channel blockers38 (39)1156 (22)
 Diuretics68 (69)1879 (36)
 Renin-angiotensin blockers68 (69)4284 (81)
  • eGFR, eGFR as measured by the Chronic Kidney Disease Epidemiology Collaboration equation; HbA1c, hemoglobin A1c.

  • a Among individuals with eGFR decline, 30 (31%) were attributed to a 50% decline in eGFR without reaching CKD stage 5 and 68 (69%) were attributed to ESRD.

  • b Baseline proteinuria measured by protein-to-creatinine ratio (mg/mg) was available in 83 of 98 individuals with eGFR decline and 3957 of 5269 individuals without eGFR decline.

  • c Albumin excretion was measured in 80 of 98 individuals with and 3048 of 5269 without eGFR decline. Microalbuminuria, >30–300 mg/g.

  • d Macroalbuminuria, ≥300 mg/g.